about
The psychomotor and cognitive effects of litoxetine in young and middle aged volunteersComparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjectsThe effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG.Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease.Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteersBiomarkers and surrogate endpointsNoise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplonAssessment of cognitive safety in clinical drug developmentPerformance testsCognitive and psychomotor performance tests and experiment design in multiple chemical sensitivityBehavioural toxicity of antidepressants with particular reference to moclobemideRupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.Effects of graded oral doses of a new 5-hydroxytryptamine/noradrenaline uptake inhibitor (Ro 15-8081) in comparison with 60 mg codeine and placebo on experimentally induced pain and side effect profile in healthy men.Effects of graded oral doses of meptazinol and pentazocine in comparison with placebo on experimentally induced pain in healthy humans.Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects.Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects.Comparison of post-operative ICU sedation between dexmedetomidine and propofol in Indian population.Hypnotic drugs, psychomotor performance and ageing.Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injuryResidual effects of zaleplon and zolpidem following middle of the night administration five hours to one hour before awakening.The placebo effect in healthy volunteers: influence of experimental conditions on physiological parameters during phase I studies.Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyPharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent.Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.Assessment of changes in psychomotor performance of elderly subjects.Effects of zolpidem on sleep architecture, night time ventilation, daytime vigilance and performance in heavy snorers.Indomethacin and cognitive function in healthy elderly volunteersPharmacodynamic effects of buspirone and clobazamA double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam.Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects.Meptazinol and pentazocine: plasma catecholamines and other effects in healthy volunteers.The effects of age on carbamazepine pharmacokinetics and adverse effects.Sedation for gastroscopy: a comparative study of midazolam and Diazemuls in patients with and without cirrhosis.The clinical assessment of analgesic drugs.The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentrationPharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects.Midazolam: effects on psychomotor performance and subjective aspects of sleep and sedation in normal volunteers.Dose tolerance to lorazepam develop with once weekly dosing?
P2860
Q24538648-506441BA-D801-484A-AD2E-67BDE81255F3Q24538962-A91BE2B7-8FED-43ED-9FFE-307CF26E5BB8Q24541290-438AA94C-6902-4BB1-B162-FB73E4D1E334Q24542426-57440FDF-9215-4B4D-92CD-3D1F5363965DQ24563637-79839563-E275-48C1-8D83-389319727617Q24678760-DEFC69DE-6C2E-468C-9142-E14EF2FB2A94Q24682992-98645837-092F-46D0-A6E4-767B8489BEFFQ28084637-1D60EBE1-2182-49F3-94FB-C86BF6162764Q28388723-D1B9F767-4E0B-4148-B062-2CE6464710D4Q28388810-0C33066D-CE9D-4EEE-9D70-6D7B0E96FC83Q29541459-2F453324-5578-43FA-86ED-6060BF75B75CQ30475256-BDCD4FB8-6905-4D7D-A8DF-A7ED18D9B653Q30498540-E5B6ABD0-D303-44E4-BFE1-99E4F6B0492DQ30498551-42B852A9-CC7A-4041-BAB4-0ED33DEE49F3Q33156940-4968E28C-5F6A-42F8-8E11-27F21BEFD92EQ33625202-6AD219FD-3294-448B-8EC2-2B0591377796Q33709795-344EE6C6-AC3D-4B95-B707-4FD23AF9AE9EQ33719445-A648B775-94FF-4475-A79C-87E13EB6DDE6Q33801294-2C70D3AA-757C-4E4A-924A-FFAFB9798B95Q33833567-43E83409-EAA4-4982-8E31-1A34D8EA0F8EQ33962137-4D4A3DB9-B433-4C18-BE54-A70D3BB8C4A8Q34058388-94DE52DA-4C78-42B8-ADC1-8CD56E302F98Q34123368-C2551180-4C07-4500-A4A6-0F0EC402B01DQ34156627-8D72E580-82DF-4888-A319-6BA759C59046Q34339795-70BE2537-D5FC-418B-8CBC-15C991D214F5Q34345599-3C59A9E5-8EE5-48D3-83EB-B3CFE61D68D9Q34346372-BE6EF186-40F8-484B-9AFC-CBCC0CA03A0FQ34346481-544B59AE-6985-4822-89F1-6435B4D7CE47Q34358579-41BDC68C-CD4F-4285-A7B3-89B3C757A7E7Q34397398-14304137-0A60-4815-8932-C28DCE3EE6C2Q34403238-57776669-6050-460A-94AE-D59552AF5E06Q34408221-85C4A263-0A83-4260-8B80-74414083B771Q34417315-B6933E19-003D-4691-AE87-19DF0371CA73Q34448173-7A932BD8-48DD-4DF6-A975-7BF69C5236EDQ34448235-9BCCF7FD-8500-4F91-AC6C-7775D7633A74Q34448736-30C27DA7-4C65-455D-B934-B8B6795A67D9Q34449479-35F737B2-F182-460D-9D2D-5D5BBFBB6805Q34492487-B6A97E9C-946F-4C10-80BE-826DC8F76C07Q34513558-9A12F8F1-D0EE-4032-9739-5ABA7BD3CEF2Q34514179-7FE22D4C-7C34-48EB-A0C1-A1E304886653
P2860
description
1980 nî lūn-bûn
@nan
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
1980年论文
@zh
1980年论文
@zh-cn
name
Psychomotor function and psychoactive drugs.
@en
type
label
Psychomotor function and psychoactive drugs.
@en
prefLabel
Psychomotor function and psychoactive drugs.
@en
P2860
P1476
Psychomotor function and psychoactive drugs.
@en
P2093
Hindmarch I
P2860
P304
P356
10.1111/J.1365-2125.1980.TB01745.X
P407
P577
1980-09-01T00:00:00Z